Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

被引：0
作者：
Maria J. G. T. Vehreschild
Petar Atanasov
Kateryna Yurko
Cristian Oancea
Georgi Popov
Valentina Smesnoi
Gheorghe Placinta
Hella Kohlhof
Daniel Vitt
Evelyn Peelen
Jelena Mihajlović
Andreas R. Muehler
机构：
[1] Goethe University Frankfurt,Department of Internal Medicine, Infectious Diseases, Medizinische Klinik II, University Hospital Frankfurt
[2] UMHATEM “N.I.Pirogov” EAD,Clinic of Internal Diseases
[3] Kharkiv National Medical University,Infectious Diseases
[4] University of Medicine and Pharmacy “Victor Babeş” Timişoara,Clinic of Infectious Disease
[5] Military Medical Academy-Sofia,undefined
[6] PMSI Clinical Hospital of Infectious Diseases “Toma Ciorba”,undefined
[7] Section 3,undefined
[8] Bulevardul Ştefan Cel Mare şi Sfânt,undefined
[9] Nr 163,undefined
[10] PMSI Clinical Hospital of Infectious Diseases “Toma Ciorba”,undefined
[11] Section 4,undefined
[12] Bulevardul Ştefan Cel Mare şi Sfânt,undefined
[13] nr 163,undefined
[14] Immunic AG,undefined
来源：
Infectious Diseases and Therapy | 2022年 / 11卷
关键词：
COVID-19; Dihydroorotate dehydrogenase inhibitor; Vidofludimus calcium;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2159 / 2176
页数：17
相关论文
共 103 条
[21]  
Biron KK(2021)Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19 JAMA Netw Open 4 247-undefined
[22]  
Stanat SC(2021)Molnupiravir in COVID-19: a systematic review of literature Diabetes Metab Syndr 15 552-undefined
[23]  
Sorrell JB(2020)Safety, tolerability and pharmacokinetics of vidofludimus calcium (IMU-838) after single and multiple ascending oral doses in healthy male subjects Eur J Drug Metab Pharmacokinet 45 763-undefined
[24]  
Bonavia A(2013)Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study J Crohns Colitis 7 2675-undefined
[25]  
Franti M(2022)A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis Ann Clin Transl Neurol 6 305-undefined
[26]  
Keaney EP(2022)A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis Hepatol Commun 365 undefined-undefined
[27]  
Kim YJ(2011)Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 13 undefined-undefined
[28]  
Cubitt B(2014)Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 81 undefined-undefined
[29]  
Cai Y(2013)Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis Neurology 2 undefined-undefined
[30]  
Xiong R(2015)Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens Neurol Neuroimmunol Neuroinflamm 10 undefined-undefined
12345678910